LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 33; pp. S1402 - S1403
Main Authors	Qin, S., Kudo, M., Meyer, T., Finn, R.S., Vogel, A., Bai, Y., Guo, Y., Meng, Z., Zhang, T., Satoh, T., Hiraoka, A., Marino, D., Assenat, E., Wyrwicz, L., Campos, M. Calvo, Hsing-Tao, K., Boisserie, F., Li, S., Chen, Y., Zhu, A.X.
Format	Journal Article
Language	English
Published	01.09.2022
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.08.033